| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma.
|
J Clin Oncol
|
2007
|
6.65
|
|
2
|
Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
|
J Clin Oncol
|
2002
|
3.30
|
|
3
|
The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas.
|
Pancreas
|
2010
|
2.43
|
|
4
|
NANETS consensus guidelines for the diagnosis of neuroendocrine tumor.
|
Pancreas
|
2010
|
1.90
|
|
5
|
Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography.
|
J Clin Oncol
|
2005
|
1.84
|
|
6
|
High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases.
|
J Clin Oncol
|
2002
|
1.79
|
|
7
|
Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with (90)Y-labeled anti-CD20 monoclonal antibody.
|
J Nucl Med
|
2002
|
1.60
|
|
8
|
Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma.
|
J Clin Oncol
|
2003
|
1.52
|
|
9
|
The NANETS consensus guidelines for the diagnosis and management of gastrointestinal neuroendocrine tumors (nets): well-differentiated nets of the distal colon and rectum.
|
Pancreas
|
2010
|
1.51
|
|
10
|
Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma.
|
Blood
|
2011
|
1.45
|
|
11
|
Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan.
|
Cancer
|
2007
|
1.41
|
|
12
|
Focal F-18 fluoro-deoxy-glucose accumulation in the lung parenchyma in the absence of CT abnormality in PET/CT.
|
J Comput Assist Tomogr
|
2007
|
1.38
|
|
13
|
The utility of restaging bone marrow biopsy in PET-negative patients with diffuse large B-cell lymphoma and baseline bone marrow involvement.
|
Am J Hematol
|
2014
|
1.23
|
|
14
|
Safety and efficacy of yttrium-90 ibritumomab tiuxetan in older patients with non-Hodgkin's lymphoma.
|
Cancer Biother Radiopharm
|
2007
|
1.22
|
|
15
|
Clinical significance of diffusely increased 18F-FDG uptake in the thyroid gland.
|
J Nucl Med
|
2007
|
1.19
|
|
16
|
Efficacy and safety of transarterial radioembolization versus chemoembolization in patients with hepatocellular carcinoma.
|
Cardiovasc Intervent Radiol
|
2012
|
1.09
|
|
17
|
The value of quantifying 18F-FDG uptake in thyroid nodules found incidentally on whole-body PET-CT.
|
Nucl Med Commun
|
2007
|
1.05
|
|
18
|
Gemcitabine radiosensitization after high-dose samarium for osteoblastic osteosarcoma.
|
Clin Cancer Res
|
2005
|
1.04
|
|
19
|
Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma.
|
Leuk Lymphoma
|
2006
|
1.02
|
|
20
|
The value of [(18)F]fluorodeoxyglucose positron emission tomography/computed tomography in extranodal natural killer/T-cell lymphoma.
|
Clin Lymphoma Myeloma
|
2008
|
1.02
|
|
21
|
A phase I multiple dose, dose escalation study of cG250 monoclonal antibody in patients with advanced renal cell carcinoma.
|
Cancer Immun
|
2007
|
0.96
|
|
22
|
The predictive value of imaging studies in evaluating regional lymph node involvement in Merkel cell carcinoma.
|
J Am Acad Dermatol
|
2012
|
0.94
|
|
23
|
Lack of impact of radioiodine therapy in tg-positive, diagnostic whole-body scan-negative patients with follicular cell-derived thyroid cancer.
|
J Clin Endocrinol Metab
|
2002
|
0.90
|
|
24
|
18F-FDG PET in the management of patients with anaplastic thyroid carcinoma.
|
Thyroid
|
2008
|
0.87
|
|
25
|
Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma.
|
J Clin Oncol
|
2002
|
0.86
|
|
26
|
Use of positron emission tomography-computed tomography in the management of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
|
Leuk Lymphoma
|
2014
|
0.85
|
|
27
|
A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and 90 yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-Hodgkin lymphoma.
|
Am J Hematol
|
2013
|
0.84
|
|
28
|
18F-FDG PET/CT in primary central nervous system lymphoma in HIV-negative patients.
|
Nucl Med Commun
|
2007
|
0.83
|
|
29
|
Hepatic vein tumor thrombus as a risk factor for excessive pulmonary deposition of microspheres during TheraSphere therapy for unresectable hepatocellular carcinoma.
|
J Vasc Interv Radiol
|
2009
|
0.83
|
|
30
|
Measuring granulocyte and monocyte accumulation at malignant lymphoma sites.
|
J Clin Oncol
|
2008
|
0.82
|
|
31
|
Impact of rituximab treatment on (90)Y-ibritumomab dosimetry for patients with non-Hodgkin lymphoma.
|
J Nucl Med
|
2009
|
0.80
|
|
32
|
A Phase II study of (153)Sm-EDTMP and high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma.
|
Am J Hematol
|
2010
|
0.79
|
|
33
|
Sensitivity and utility of parathyroid scintigraphy in patients with primary versus secondary and tertiary hyperparathyroidism.
|
World J Surg
|
2006
|
0.79
|
|
34
|
Contribution of F-18 FDG PET-CT in the detection of systemic spread of primary central nervous system lymphoma.
|
Clin Nucl Med
|
2007
|
0.79
|
|
35
|
18F-FDG PET and PET/CT in Burkitt's lymphoma.
|
Eur J Radiol
|
2009
|
0.79
|
|
36
|
Prognostic value of 18F-fluorodeoxyglucose-positron emission tomography in patients with differentiated thyroid carcinoma and circulating antithyroglobulin autoantibodies.
|
Nucl Med Commun
|
2011
|
0.79
|
|
37
|
The prognostic value of 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography in patients with suspected residual or recurrent medullary thyroid carcinoma.
|
Mol Imaging Biol
|
2009
|
0.78
|
|
38
|
Progress in gene therapy for prostate cancer.
|
Front Oncol
|
2012
|
0.78
|
|
39
|
Outcome prediction in heart failure with atrial fibrillation: relative role of left ventricular ejection fraction and neurohormonal measures.
|
J Nucl Cardiol
|
2013
|
0.77
|
|
40
|
Marrow irradiation with high-dose 153Samarium-EDTMP followed by chemotherapy and hematopoietic stem cell infusion for acute myelogenous leukemia.
|
Leuk Lymphoma
|
2006
|
0.76
|
|
41
|
Liver transplantation after radioembolization in a patient with unresectable HCC.
|
Nat Rev Gastroenterol Hepatol
|
2009
|
0.76
|
|
42
|
Low toxicity and efficacy of (153)samarium-EDTMP and melphalan as a conditioning regimen for secondary acute myelogenous leukemia.
|
Pediatr Transplant
|
2005
|
0.75
|
|
43
|
Assessment of Lymphoma Therapy Using (18)F-FDG PET.
|
J Nucl Med
|
2002
|
0.75
|
|
44
|
Safety and efficacy of external beam radiation therapy for non-Hodgkin lymphoma in patients with prior 90Y-ibritumomab tiuxetan radioimmunotherapy.
|
Cancer
|
2006
|
0.75
|